Why TP53 status does not associate with clinical endpoints in ovarian cancer: Facts and hypotheses

Crijns, 2003, Prognostic factors in ovarian cancer: current evidence and future prospects, Eur. J. Cancer, 39, 127, 10.1016/S1359-6349(03)90017-6

Baekelandt, 1999, Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer, J. Clin. Oncol., 17, 2061, 10.1200/JCO.1999.17.7.2061

Hartmann, 1994, Prognostic significance of p53 immunostaining in epithelial ovarian cancer, J. Clin. Oncol., 12, 64, 10.1200/JCO.1994.12.1.64

Ferrandina, 1999, p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer, Br. J. Cancer, 81, 733, 10.1038/sj.bjc.6690756

Eltabbakh, 1997, p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer, Cancer, 80, 892, 10.1002/(SICI)1097-0142(19970901)80:5<892::AID-CNCR10>3.0.CO;2-R

Kupryjańczyk, 2003, Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen, Br. J. Cancer, 88, 848, 10.1038/sj.bjc.6600789

Brown, 1996, Cellular responses to DNA damage and cisplatin resistance

Fajac, 1996, Cisplatin-induced apoptosis and p53 gene status in a cisplatin-resistant human ovarian carcinoma cell line, Int. J. Cancer, 68, 67, 10.1002/(SICI)1097-0215(19960927)68:1<67::AID-IJC13>3.0.CO;2-3

Gallagher, 1997, Identification of p53 genetic suppressor elements which confer resistance to cisplatin, Oncogene, 14, 185, 10.1038/sj.onc.1200813

Coukos, 1998, Chemotherapy resistance in ovarian cancer: new molecular perspectives, Obstet. Gynecol., 91, 783, 10.1016/S0029-7844(98)00054-4

Dogan, 2005, p53 and mdm2 as prognostic indicators in patients with epithelial ovarian cancer: a multivariate analysis, Gynecol. Oncol., 97, 46, 10.1016/j.ygyno.2004.12.053

Kupryjańczyk, 2004, TP53 status determines prognostic and predictive factors in ovarian carcinomas, 93

Kupryjańczyk, 2004, TP53 status determines clinical significance of ERBB2 expression in ovarian cancer, Br. J. Cancer, 91, 1916, 10.1038/sj.bjc.6602238

Pegram, 1997, The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells, Oncogene, 15, 537, 10.1038/sj.onc.1201222

Bellamy, 1997, p53 and apoptosis, Br. Med. Bull., 53, 522, 10.1093/oxfordjournals.bmb.a011628

Hawkins, 1996, Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents, Cancer Res., 56, 892

Sionov, 1999, The cellular response to p53: the decision between life and death, Oncogene, 18, 6145, 10.1038/sj.onc.1203130

Havrilesky, 2003, Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study, J. Clin. Oncol., 21, 3814, 10.1200/JCO.2003.11.052

Righetti, 1996, A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma, Cancer Res., 56, 689

Buttitta, 1997, p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study, Br. J. Cancer, 75, 230, 10.1038/bjc.1997.38

Lincet, 2000, The p21(cip1/waf1) cyclin-dependent kinase inhibitor enhances the cytotoxic effect of cisplatin in human ovarian carcinoma cells, Cancer Lett., 161, 17, 10.1016/S0304-3835(00)00586-3

Huang, 2002, Dominant negative knockout of p53 abolishes ErbB2-dependent apoptosis and permits growth acceleration in human breast cancer cells, Br. J. Cancer, 86, 1104, 10.1038/sj.bjc.6600219

Casalini, 2001, Role of p53 in HER2-induced proliferation or apoptosis, J. Biol. Chem., 276, 12449, 10.1074/jbc.M009732200